Ergotamine in the acute treatment of migraine -: A review and European consensus

被引：240

作者：

Tfelt-Hansen, P

Saxena, PR

Dahlöf, C

Pascual, J

Láinez, M

Henry, P

Diener, HC

Schoenen, J

Ferrari, MD

Goadsby, PJ

机构：

[1] Glostrup Cty Hosp, Dept Neurol, Copenhagen, Denmark

[2] Erasmus Univ, Med Ctr, Dept Pharmacol, Rotterdam, Netherlands

[3] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands

[4] Gothenburg Migraine Clin, Gothenburg, Sweden

[5] Univ Hosp Marques Valdecilla, Serv Neurol, Santander, Spain

[6] Hosp Gen Univ, Valencia, Spain

[7] CHU Hosp Pellegrin, Serv Neurol, Bordeaux, France

[8] Univ Essen Gesamthsch, Neurol Klin & Poliklin, Essen, Germany

[9] Univ Liege, Dept Neurol, Liege, Belgium

[10] Univ Liege, Dept Neuroanat, Liege, Belgium

[11] UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England

来源：

BRAIN | 2000年 / 123卷

关键词：

migraine; headache; acute treatment; serotonin pharmacology; 5-HT1B/1D receptors;

D O I：

10.1093/brain/123.1.9

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific antimigraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.

引用

页码：9 / 18

页数：10

共 83 条

[1]

ADAMS M, 1971, PRACTITIONER, V206, P551

[2] CLONING OF ANOTHER HUMAN SEROTONIN RECEPTOR (5-HT1F) - A 5TH 5-HT1 RECEPTOR SUBTYPE COUPLED TO THE INHIBITION OF ADENYLATE-CYCLASE [J].